Aerie Pharmaceuticals, Inc.

Good afternoon. Thank you for standing by, and welcome to the Aerie Pharmaceuticals' fourth quarter and full year 2021 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. Today's conference will be recorded. It is now my pleasure to turn the floor over to Hans Wittstum of LifeSide Partners, Aerie's investor relations firm.

Please go ahead.

Thank you, Operator. Good afternoon, and thank you for joining us. With us today are Raj Kennan, Chief Executive Officer, Michelle Senchina, Head of Clinical Development and Medical Affairs, and Jeff Calabrese, Principal Accounting Officer. Today's call is also being webcast live on our website, investors.arypharma.com, and it will be available for replay, as indicated in our press release. Now, for forward-looking statements and non-GAAP financial measures. On this call, we will make certain forward-looking statements, including statements, forecasts, and observations regarding our future financial and operating performance and impacts of the COVID-19 pandemic and its variants, including our observations regarding ongoing operating expenses and net revenue per bottle. These statements will include observations associated with our commercialization of Ropressa and Roklatan in the United States and our collaborations in Japan, Europe, and other regions of the world. They will also include plans and expectations regarding the success, timing, and cost of our clinical trials. Additionally, we will discuss progress regarding maintaining, requesting, or obtaining approvals from regulatory agencies of our products and product candidates, along with the associated business strategies regarding these products and product candidates. Finally, we will address our financial liquidity and other statements related to future events, including our financial outlook for 2022. These statements are based on the beliefs and expectations of management as of today. Our actual results may differ materially from our expectations. Investors should read carefully the risks and uncertainties described in today's press release, as well as the risk factors included in our filings with the SEC. We assume no obligation to revise or update forward-looking statements, whether as the result of new information, future events, or otherwise. Please note that we will file our Form 10-K tomorrow. In addition, during this call, we will be discussing certain adjusted or non-GAAP financial measures. For additional disclosures relating to these non-GAAP financial measures, including a reconciliation to the comparable GAAP measures, please see today's press release, which is posted on the Investor Relations section of our website. And with that, I will now turn the call over to Raj Kanan, the CEO of ARRI. Raj?